keyword
MENU ▼
Read by QxMD icon Read
search

Infection acute myeloid leukaemia

keyword
https://www.readbyqxmd.com/read/27891349/unusual-presentation-of-acute-leukaemia-a-tripod-of-cases
#1
Manjari Kishore, Vijay Kumar, Sadhna Marwah, Abhay S Nigam
Acute Leukemia is one of the common haematological malignancies encountered with varied clinical and haematological presentation. In acute leukaemia, complications like bleeding and infection cause significant morbidity and mortality, thus overshadowing the thromboembolic events. Among the various malignant haematological disorders, the association of thromboembolic events is often noted with acute promyelocytic leukemia, though the overall frequency of such events remains very low. Acute Lymphoblastic Leukemia (ALL) is, however, more common than Acute non-lymphoblastic Leukaemia...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27830376/clinical-effectiveness-of-itraconazole-as-antifungal-prophylaxis-in-aml-patients-undergoing-intensive-chemotherapy-in-the-modern-era
#2
C L Keighley, P Manii, S R Larsen, S van Hal
Antifungal prophylaxis regimens vary between centres, informed by local epidemiology and antifungal stewardship practices. The advantages of itraconazole over posaconazole prophylaxis include maintaining the utility of azole therapy for suspected breakthrough invasive fungal infection (bIFI). We examined the effectiveness and tolerability of itraconazole as prophylaxis in acute myeloid leukaemia (AML) patients. We sought to determine the rate of probable and proven bIFI in the context of itraconazole prophylaxis in a real-life setting...
November 9, 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27790720/a-phase-2-trial-of-high-dose-lenalidomide-in-patients-with-relapsed-refractory-higher-risk-myelodysplastic-syndromes-and-acute-myeloid-leukaemia-with-trilineage-dysplasia
#3
Amer M Zeidan, B Douglas Smith, Hetty E Carraway, Ivana Gojo, Amy DeZern, Steven D Gore
Limited therapies exist for patients with refractory and relapsed (RR) higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukaemia with trilineage dysplasia (AML-TD). High dose (HD) lenalidomide (50 mg) has activity as frontline therapy in elderly AML but there is limited data in the RR setting. This phase II trial included patients with RR HR-MDS or AML-TD at 2 doses of lenalidomide (15 or 50 mg) on days 1-28 of 42-day cycles. The primary endpoint was response rate using the 2006 International Working Group criteria...
October 28, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27667012/long-lasting-protective-effect-of-posaconazole-prophylaxis-in-patients-with-acute-myeloid-leukemia-receiving-allogeneic-hematopoietic-stem-cell-transplantation
#4
Alessandro Busca, Anna Candoni, Ernesta Audisio, Roberto Passera, Benedetto Bruno, Federico Monaco, Nicola Mordini, Adriana Vacca, Mario Delia, Franco Aversa, Livio Pagano
Patients with acute myeloid leukemia (AML) during induction chemotherapy and those who receive allogeneic hematopoietic stem cell transplantation (HSCT) are at higher risk of invasive fungal infections (IFI). In the present study, we investigated whether the risk of IFI in AML patients receiving HSCT might be affected by the antifungal prophylaxis with posaconazole administered during the induction/salvage chemotherapy treatment. Between August 2001 and April 2015, 130 patients with AML received itraconazole/fluconazole (group A) and 99 received posaconazole (group B) as antifungal prophylaxis after induction/salvage chemotherapy at 7 Italian centers and all patients received fluconazole as antifungal prophylaxis after HSCT...
September 22, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27374466/infusion-of-a-non-hla-matched-ex-vivo-expanded-cord-blood-progenitor-cell-product-after-intensive-acute-myeloid-leukaemia-chemotherapy-a-phase-1-trial
#5
Colleen Delaney, Filippo Milano, Laura Cicconi, Megan Othus, Pamela S Becker, Vicky Sandhu, Ian Nicoud, Ann Dahlberg, Irwin D Bernstein, Frederick R Appelbaum, Elihu H Estey
BACKGROUND: The intensive chemotherapy regimens used to treat acute myeloid leukaemia routinely result in serious infections, largely due to prolonged neutropenia. We investigated the use of non-HLA-matched ex-vivo expanded cord blood progenitor cells to accelerate haemopoietic recovery and reduce infections after chemotherapy. METHODS: We enrolled patients with a diagnosis of acute myeloid leukaemia by WHO criteria and aged 18-70 years inclusive at our institution (Fred Hutchinson Cancer Research Center) into this phase 1 trial...
July 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27346972/extreme-hyperferritinemia-in-the-setting-of-acute-myeloid-leukaemia-a-case-report-of-hemophagocytic-lymphohistiocytosis
#6
Damien Denimal, Louise Ménégaut, Cédric Rossi, Laurence Duvillard, David Masson
INTRODUCTION: Major hyperferritinemia is a rare feature in clinical laboratories associated with a wide variety of disorders, including hemophagocytic lymphohistiocytosis (HLH). The diagnosis of HLH is based on clinical and biological criteria, such as those proposed by the Histiocyte Society. However, several of these criteria are not relevant in the specific setting of hematologic malignancies. MATERIALS AND METHODS: A 69-year-old male was treated for an acute myeloid leukaemia...
2016: Biochemia Medica: časopis Hrvatskoga Društva Medicinskih Biokemičara
https://www.readbyqxmd.com/read/27264037/potentially-avoidable-hospital-admissions-in-older-patients-with-acute-myeloid-leukaemia-in-the-usa-a-retrospective-analysis
#7
Areej El-Jawahri, Tanya Keenan, Gregory A Abel, David P Steensma, Thomas W LeBlanc, Yi-Bin Chen, Gabriela Hobbs, Lara Traeger, Amir T Fathi, Daniel J DeAngelo, Martha Wadleigh, Karen K Ballen, Philip C Amrein, Richard M Stone, Jennifer S Temel
BACKGROUND: Older adults (≥60 years of age) with acute myeloid leukaemia spend a substantial proportion of their life in hospital after diagnosis. We examined reasons for their hospital admissions and identified potentially avoidable hospital admissions (PAH) in this age group in the USA. METHODS: In this retrospective analysis, we examined the reasons for hospital admissions in older patients diagnosed with and treated for acute myeloid leukaemia at two tertiary care hospitals in the USA...
June 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27161689/po-02-retrospective-audit-of-the-peripherally-inserted-central-catheter-picc-associated-thrombosis-in-patients-with-haematological-malignancies-at-cork-university-hospital
#8
E McAuliffe, S O'Shea, M I Khan
INTRODUCTION: Peripherally inserted central catheters (PICC) have been increasingly used for administration of chemotherapy, antibiotics and blood products in patients with haematological malignancies. Although generally regarded safe, infections and thrombotic events have occurred with PICC use, necessitating study to guide future clinical prophylaxis and management. AIM: 1) Determine the incidence of PICC associated thrombosis in patients with haematological malignancies 2) To identify clinically significant risk factors contributing to these complications...
April 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27061932/a-cluster-of-geotrichum-clavatum-saprochaete-clavata-infection-in-haematological-patients-a-first-italian-report-and-review-of-literature
#9
Maria Ilaria Del Principe, Loredana Sarmati, Mariagiovanna Cefalo, Carla Fontana, Giovanna De Santis, Francesco Buccisano, Luca Maurillo, Eleonora De Bellis, Massimiliano Postorino, Giuseppe Sconocchia, Giovanni Del Poeta, Maurizio Sanguinetti, Sergio Amadori, Livio Pagano, Adriano Venditti
Invasive fungal infections, usually Aspergillus and Candida, represent a major cause of morbidity and mortality in patients with malignant haematological diseases, but in the last years rare fungal infections have more frequently been reported. Here, we report the clinical history of three patients affected with haematological malignancies who developed an infection caused by Geotrichum (G.) clavatum. Two out of three patients were affected by acute myeloid leukaemia (AML), and one by mantle cell lymphoma (MCL)...
September 2016: Mycoses
https://www.readbyqxmd.com/read/27027972/invasive-fungal-infections-in-aml-mds-patients-treated-with-azacitidine-a-risk-worth-considering-antifungal-prophylaxis
#10
Helena Pomares, Montserrat Arnan, Isabel Sánchez-Ortega, Anna Sureda, Rafael F Duarte
The aim of this study is to analyse the risk of invasive fungal infection (IFI) and the need for antifungal prophylaxis in patients with acute myeloid leukaemia and myelodysplastic syndromes (AML/MDS) treated with azacitidine. We retrospectively analysed the incidence of IFI according to EORTC-MSG criteria in 121 consecutive AML/MDS patients receiving 948 azacitidine courses (median 5, range 1-43) between June 2007 and June 2015. Four cases of IFI (two possible, one probable aspergillosis and one proven candidemia) occurred in this series...
August 2016: Mycoses
https://www.readbyqxmd.com/read/26967515/a-systematic-evaluation-of-the-safety-and-toxicity-of-fingolimod-for-its-potential-use-in-the-treatment-of-acute-myeloid-leukaemia
#11
Anoop K Enjeti, Angel D'Crus, Kathleen Melville, Nicole M Verrills, Philip Rowlings
Treatment of acute myeloid leukaemia (AML) is challenging and emerging treatment options include protein phosphatase 2A (PP2A) activators. Fingolimod is a known PP2A activator that inhibits multiple signalling pathways and has been used extensively in patients with multiple sclerosis and other indications. The initial positive results of PP2A activators in vitro and mouse models of AML are promising; however, its safety for use in AML has not been assessed. From human studies of fingolimod in other indications, it is possible to evaluate whether the safety and toxicity profile of the PP2A activators will allow their use in treating AML...
July 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/26954719/predicting-microbiologically-defined-infection-in-febrile-neutropenic-episodes-in-children-global-individual-participant-data-multivariable-meta-analysis
#12
Robert S Phillips, Lillian Sung, Roland A Amman, Richard D Riley, Elio Castagnola, Gabrielle M Haeusler, Robert Klaassen, Wim J E Tissing, Thomas Lehrnbecher, Julia Chisholm, Hana Hakim, Neil Ranasinghe, Marianne Paesmans, Ian M Hann, Lesley A Stewart
BACKGROUND: Risk-stratified management of fever with neutropenia (FN), allows intensive management of high-risk cases and early discharge of low-risk cases. No single, internationally validated, prediction model of the risk of adverse outcomes exists for children and young people. An individual patient data (IPD) meta-analysis was undertaken to devise one. METHODS: The 'Predicting Infectious Complications in Children with Cancer' (PICNICC) collaboration was formed by parent representatives, international clinical and methodological experts...
March 15, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/26880256/granulocyte-and-granulocyte-macrophage-colony-stimulating-factors-for-newly-diagnosed-patients-with-myelodysplastic-syndromes
#13
REVIEW
Franz Hutzschenreuter, Ina Monsef, Karl-Anton Kreuzer, Andreas Engert, Nicole Skoetz
BACKGROUND: Myelodysplastic syndromes (MDS) are a heterogeneous group of haematological diseases which are characterised by a uni- or multilineage dysplasia of haematological stem cells. Standard treatment is supportive care of the arising symptoms including red blood cell transfusions or the administration of erythropoiesis-stimulating agents (ESAs) in the case of anaemia or the treatment with granulocyte (G-CSF) and granulocyte-macrophage colony stimulating factors (GM-CSF) in cases of neutropenia...
February 16, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26865204/pulmonary-fungal-infections-in-patients-with-acute-myeloid-leukaemia-is-it-the-time-to-revise-the-radiological-diagnostic-criteria
#14
Francesca Maccioni, Simone Vetere, Carlo De Felice, Najwa Al Ansari, Alessandra Micozzi, Giuseppe Gentile, Robin Foà, Corrado Girmenia
The definition of pulmonary fungal infections (PFI) according to the EORTC-MSG criteria may lack diagnostic sensitivity due to the possible presentation of PFI with different radiological pictures. We evaluated the hypothesis to apply less restrictive radiological criteria to define PFI in patients with acute myeloid leukaemia (AML) submitted to chemotherapy. Overall, 73 consecutive episodes of pulmonary infiltrates associated to positive serum galactomannan test or fungal isolation or galactomannan detection from respiratory specimens were considered...
June 2016: Mycoses
https://www.readbyqxmd.com/read/26766286/cord-blood-transplant-for-acute-myeloid-leukaemia
#15
REVIEW
Karen K Ballen, Hillard Lazarus
Umbilical cord blood is a haematopoietic progenitor cell source for patients with acute myeloid leukaemia (AML), other haematological malignancies and metabolic diseases who can be cured by allogeneic haematopoietic cell transplantation, but who do not have a human leucocyte antigen compatible related or unrelated donor. Although the first cord blood transplants were done in children, there are currently more cord blood transplants performed in adults. In this review, we explore the history of umbilical cord blood transplantation, paediatric and adult outcome results, and novel trends to improve engraftment and reduce infection...
April 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26685771/outcomes-after-use-of-two-standard-ablative-regimens-in-patients-with-refractory-acute-myeloid-leukaemia-a-retrospective-multicentre-registry-analysis
#16
Arnon Nagler, Bipin N Savani, Myriam Labopin, Emmanuelle Polge, Jakob Passweg, Jürgen Finke, Slawomira Kyrcz-Krzemien, Liisa Volin, Achilles Anagnostopoulos, Mahmoud Aljurf, Dietrich W Beelen, Stephane Vigouroux, Noel Milpied, Felipe Suarez, Mohamad Mohty
BACKGROUND: Cyclophosphamide plus intravenous busulfan has not been compared with cyclophosphamide plus total body irradiation (TBI) in adults with advanced refractory acute myeloid leukaemia before allogeneic haemopoietic stem-cell transplantation (HCT). We aimed to assess whether survival of patients receiving ablative intravenous busulfan-based conditioning regimens before a related or volunteer-unrelated donor HCT for refractory acute myeloid leukaemia is not inferior to that of patients receiving an ablative TBI-based regimen...
September 2015: Lancet Haematology
https://www.readbyqxmd.com/read/26611101/-nocardia-veterana-bacteraemia-after-a-lung-infection-in-a-patient-with-acute-myeloid-leukaemia
#17
Ana Arroyo-Fajardo, Paloma Troyano-Hernández, Alma Sotillo, María Pilar Romero-Gómez
No abstract text is available yet for this article.
August 2016: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/26608844/pseudozyma-aphidis-fungaemia-with-invasive-fungal-pneumonia-in-a-patient-with-acute-myeloid-leukaemia-case-report-and-literature-review
#18
Hyonsoo Joo, Yeon-Geun Choi, Sung-Yeon Cho, Jae-Ki Choi, Dong-Gun Lee, Hee-Je Kim, Irene Jo, Yeon-Joon Park, Kyo-Young Lee
Pseudozyma species rarely cause invasive diseases in humans, which are usually isolated from plants. There have been anecdotal reports regarding Pseudozyma species infections in patients with underlying diseases or in neonates. However, clinical data and the pathogenicity in humans are still insufficient. We experienced a case of Pseudozyma aphidis fungaemia with invasive fungal pneumonia that developed during reinduction chemotherapy in a 51-year-old male with acute myeloid leukaemia (AML). P. aphidis was suspected based on the morphology of the yeast isolated from the blood and was confirmed via rDNA gene sequencing analysis...
January 2016: Mycoses
https://www.readbyqxmd.com/read/26549589/addition-of-sorafenib-versus-placebo-to-standard-therapy-in-patients-aged-60-years-or-younger-with-newly-diagnosed-acute-myeloid-leukaemia-soraml-a-multicentre-phase-2-randomised-controlled-trial
#19
RANDOMIZED CONTROLLED TRIAL
Christoph Röllig, Hubert Serve, Andreas Hüttmann, Richard Noppeney, Carsten Müller-Tidow, Utz Krug, Claudia D Baldus, Christian H Brandts, Volker Kunzmann, Hermann Einsele, Alwin Krämer, Kerstin Schäfer-Eckart, Andreas Neubauer, Andreas Burchert, Aristoteles Giagounidis, Stefan W Krause, Andreas Mackensen, Walter Aulitzky, Regina Herbst, Mathias Hänel, Alexander Kiani, Norbert Frickhofen, Johannes Kullmer, Ulrich Kaiser, Hartmut Link, Thomas Geer, Albert Reichle, Christian Junghanß, Roland Repp, Frank Heits, Heinz Dürk, Jana Hase, Ina-Maria Klut, Thomas Illmer, Martin Bornhäuser, Markus Schaich, Stefani Parmentier, Martin Görner, Christian Thiede, Malte von Bonin, Johannes Schetelig, Michael Kramer, Wolfgang E Berdel, Gerhard Ehninger
BACKGROUND: Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the treatment of acute myeloid leukaemia. We investigated the efficacy and tolerability of sorafenib versus placebo in addition to standard chemotherapy in patients with acute myeloid leukaemia aged 60 years or younger. METHODS: This randomised, double-blind, placebo-controlled, phase 2 trial was done at 25 sites in Germany...
December 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26544114/interleukin-2-as-maintenance-therapy-for-children-and-adults-with-acute-myeloid-leukaemia-in-first-complete-remission
#20
REVIEW
Chen Mao, Xiao-Hong Fu, Jin-Qiu Yuan, Zu-Yao Yang, Ya-Fang Huang, Qian-Ling Ye, Xin-Yin Wu, Xue-Feng Hu, Zhi-Min Zhai, Jin-Ling Tang
BACKGROUND: Acute myeloid leukaemia (AML) is a malignant cancer of hematopoietic stem cells. The treatment of AML consists of two treatment phases: the remission induction phase to achieve a rapid, complete remission (CR) and the consolidation phase to achieve a durable molecular remission. People in CR are at risk of AML relapse, and people with relapsed AML have poor survival prospects. Thus, there is a continuous need for treatments to further improve prognosis. Interleukin-2 (IL-2), an immune-stimulatory cytokine, is an alternative to standard treatment for people with AML to maintain the efficacy after consolidation therapy...
November 6, 2015: Cochrane Database of Systematic Reviews
keyword
keyword
22643
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"